In a trial of metastatic triple-negative breast cancer, AZD5363 significantly extended patients’ overall survival from 12.6 to 19.1 months, vs. placebo, when given with chemotherapy.
A Spark Of Good News For Precision Oncology In Breast Cancer
In a trial of metastatic triple-negative breast cancer, AZD5363 significantly extended patients’ overall survival from 12.6 to 19.1 months, vs. placebo, when given with chemotherapy.